The blood testing startup Theranos, once favored by the well connected in Washington, has hit a costly new roadblock. Elizabeth Holmes' (WOT:nonperson) startup went through the expensive process of developing a blood test for the Zika virus which they can't market because they botched up the paperwork documenting their testing again while further breaking patient safety rules. Theranos appears to be giving up on recouping the development costs for their test and they withdrawn their application to the FDA. It is still possible for Theranos to reapply after conducting further testing that complies with patient safety rules. Tim Draper (WOT:nonperson) was not solicited for comment and is assumed to still be bullish on Theranos. Sorry for your loss.